Sandoz announces winners of inaugural Healthcare Access Challenge #SandozHACk

NovartisSandoz, a Novartis Division, announced today the three winners of the inaugural Healthcare Access Challenge (Sandoz HACk). The winners, chosen by a panel of judges at the Wired Health 2017 event in London, identified innovative approaches to address challenges in Ghana, the Maldives and the Philippines. The winning ideas all proposed novel ways to use mobile technologies to connect patients with caregivers and essential medicines, addressing access issues specific to their country but with the potential for solutions to be applied elsewhere.

The three winners were chosen from six finalists, out of a total of approximately 150 ideas submitted from 30 countries. All six presented their ideas to a panel of judges at Wired Health 2017, as part of the HACk "Live in London 2017" event.

Announcing the winners, Sandoz CEO and Division Head Richard Francis said: "Despite all the advances in modern medicine, universal access to healthcare is still arguably the single largest unmet medical need for people around the world."

He added: "We believe that the biggest changes often come from amazing, small ideas - and that the only thing standing between a good idea and a great idea is often just a bit of support at the right time. I see the future of medicine being driven by strong collaboration between healthcare companies and external partners. The Sandoz HACk is one way that we are trying to make this vision a reality."

Roberto Ascione, CEO of Healthware International and a member of the Sandoz HACk 2017 judging panel, said: "Increasing access to healthcare is one of the major challenges facing mankind today. No one person, or organization, can solve this on their own - that's why we all need to work together to find practical solutions to real problems. That's what Sandoz HACk is all about, and why I'm proud to be part of this great new access initiative."

To help support development of the six ideas prior to pitching them at Wired Health 2017, all six were given the chance to receive feedback from OpenIDEO, a global community of creative thinkers, technologists and others interested in helping social entrepreneurs. That feedback was also supplemented by contributions from functional experts within Sandoz.

The three winners, who will now receive EUR 20,000 each in funding to "bring their ideas to life" as well as ongoing support from Sandoz experts, are:

  • Blood Drive - in the Maldives, one out of 120 newborns has blood condition thalassemia. 85% of these children will not survive until age five unless they receive regular blood transfusions, but the scattered nature of the islands makes coordinating blood donations and banks very hard. This idea from Mohammed Shuraih and Yameen Rasheed aims to link islanders with a database of hospitals, who can send updates when they are running blood donation programs and use geolocation alerts to everyone nearby so that they can donate blood.
  • GoPharma - In Ghana, pharmacists don't generally work in rural areas and pharmacies are staffed by unskilled workers. This idea from Elvin Blankson and Priscilla Adu-Darko would connect pharmacists in towns with rural pharmacies, to make virtual appointments for advice on how to take medicines, contraindications etc.
  • Save-a-life - In the Philippines, basic first aid skills are mandated for inclusion in basic education, to help with the fact that ambulances find it hard to reach accidents quickly, given the distances involved and the challenging geography of the island nation. But most people don't yet have these skills. This app idea from Joel Alejandro and Andrea Relucio will help Filipinos who don't have the necessary training to perform CPR using auditory and visual guides, while also notifying emergency services.

For further information, please visit:
https://www.sandoz.com/making-access-happen

About the Sandoz HACk
Despite all the advances in modern medicine, universal access to healthcare is still arguably the single largest unmet medical need. At Sandoz we believe that the biggest changes often come from amazing, small ideas. Sometimes, the only difference between a good idea and a great idea is a little bit of support. That is where Sandoz HACk comes in – the Healthcare Access Challenge.

In September 2016 we called on young (18-35) creative thinkers to ‘re-imagine healthcare access’ and enter Sandoz HACk.

Using social media, we promoted the Sandoz HACk and asked for ideas that use mobile technology (M-Health) to connect people to better health.

Over the course of two months, we received around 150 ideas from over 30 countries. These were narrowed down to six finalists who were invited to come to London in March 2017 to present their ideas to a panel of judges at WIRED Health 2017. There, the six ideas were narrowed down to three winners from Ghana, the Maldives and the Philippines, each of whom will receive EUR 20,000 and ongoing mentorship to help make their idea a reality.

To ensure that the finalists were all equally well positioned for success, we gave them the opportunity to refine their ideas with feedback from OpenIDEO, a global community of creative thinkers, technologists and others interested in helping social entrepreneurs. That feedback was also supplemented by contributions from experts from Sandoz.

About Sandoz Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people's lives. We contribute to society's ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1000 molecules, covering all major therapeutic areas, accounted for 2016 sales of USD 10.1 billion. In 2016, our products reached well over 500 million patients and we aspire to reach one billion. Sandoz is headquartered in Holzkirchen, in Germany's Greater Munich area.

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Abbott recommends rejection of below-market mini-T…

Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing approx...

Scorpion venom to shuttle drugs into the brain

The Peptides and Proteins lab at the Institute for Research in Biomedicine (IRB Barcelona) has published a paper in Chemical Communications describing the capacity of a s...

AstraZeneca to divest US Synagis rights to Sobi

AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncyt...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Syntropy to unlock the value of scientific data in…

Merck, a leading science and technology company, and software company Palantir Technologies, today announced their intent to form a joint venture under the brand name Syn...